Mark R. Ziebell
2022
In 2022, Mark R. Ziebell earned a total compensation of $1.3M as Vice President, General Counsel and Corporate Secretary at Peregrine Pharmaceuticals, a 22% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $247,075 |
|---|---|
| Salary | $414,000 |
| Stock Awards | $580,260 |
| Other | $50,373 |
| Total | $1,291,708 |
Ziebell received $580.3K in stock awards, accounting for 45% of the total pay in 2022.
Ziebell also received $247.1K in non-equity incentive plan, $414K in salary and $50.4K in other compensation.
Rankings
In 2022, Mark R. Ziebell's compensation ranked 2,535th out of 5,736 executives tracked by ExecPay. In other words, Ziebell earned more than 55.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,535 out of 5,736 | 56th |
Division Manufacturing | 1,401 out of 3,125 | 55th |
Major group Chemicals And Allied Products | 638 out of 1,416 | 55th |
Industry group Drugs | 592 out of 1,317 | 55th |
Industry Pharmaceutical Preparations | 424 out of 963 | 56th |
Source: SEC filing on August 29, 2022.
Ziebell's colleagues
We found two more compensation records of executives who worked with Mark R. Ziebell at Peregrine Pharmaceuticals in 2022.
News
Peregrine Pharmaceuticals CEO Nicholas Green's 2023 pay rises 5% to $6.5M
August 28, 2023
Peregrine Pharmaceuticals CEO Nicholas Green's 2022 pay jumps 117% to $6.2M
August 29, 2022
Peregrine Pharmaceuticals CEO Nicholas Green receives $2.8M in 2021
August 27, 2021
Peregrine Pharmaceuticals General Counsel Mark Ziebell's 2020 pay jumps 124% to $1.1M
August 27, 2020
Peregrine Pharmaceuticals CEO Roger Lias' 2019 pay jumps 25% to $880K
August 21, 2019
Peregrine Pharmaceuticals CEO Roger Lias receives $704K in 2018
August 17, 2018